David Rolfe
Wedgewood Partners
David Rolfe Edwards Lifesciences Corp stake
total: 97
Wedgewood Partners EW trades
- Total transactions:
- 37
- New positions:
- 1
- Added:
- 8
- Reduced:
- 28
- Held since:
- 2017 Q1
- Held for:
- 37 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, David Rolfe holds 170,969 Edwards Lifesciences Corp (EW) shares with a market value of roughly $13.69M accounting for 2.83% of the overall portfolio. To date, the estimated cost basis is nearly $34.39 for "buy" trades and estimated average "sell" price is $59.37. Wedgewood Partners first purchased EW in 2017 Q1, initially acquiring about 3.41M shares. Since the initial investment in Edwards Lifesciences Corp (EW), Wedgewood Partners has made 36 more transactions.
When did David Rolfe buy Edwards Lifesciences Corp (EW)?
David Rolfe first invested in Edwards Lifesciences Corp (EW) in 2017 Q1 at the reported quarter-end price of $31.36 per share.
What's the cost basis of Wedgewood Partners's EW stake?
The estimated cost basis for Edwards Lifesciences Corp (EW) stake is around $34.39 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $34.39
- Weighted AVG sell price:
- $59.37
David Rolfe's historical trades in Edwards Lifesciences Corp
37 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.83%
|
170,969
|
$80.08
|
$13,691,198
|
-5.48% (-9,913)
|
-0.15%
|
|
2025 Q4
|
2.88%
|
180,882
|
$85.25
|
$15,420,191
|
-2.07% (-3,819)
|
-0.06%
|
|
2025 Q3
|
2.62%
|
184,701
|
$77.77
|
$14,364,197
|
+3.74% (+6,667)
|
+0.09%
|
|
2025 Q2
|
2.77%
|
178,034
|
$80.09
|
$14,258,743
|
-7.19% (-13,784)
|
-0.22%
|
|
2025 Q1
|
2.97%
|
191,818
|
$76.75
|
$14,722,032
|
-43.49% (-147,618)
|
-2.23%
|
|
2024 Q4
|
4.95%
|
339,436
|
$74.03
|
$25,128,447
|
-5.52% (-19,821)
|
-0.27%
|
|
2024 Q3
|
4.34%
|
359,257
|
$66.52
|
$23,897,776
|
+1.36% (+4,830)
|
+0.06%
|
|
2024 Q2
|
4.74%
|
354,427
|
$65.54
|
$23,229,146
|
+44.40% (+108,976)
|
+1.46%
|
|
2024 Q1
|
4.43%
|
245,451
|
$90.16
|
$22,129,862
|
-2.07% (-5,201)
|
-0.1%
|
|
2023 Q4
|
4.55%
|
250,652
|
$86.26
|
$21,621,198
|
+29.34% (+56,855)
|
+1.03%
|
|
2023 Q3
|
3.21%
|
$69.28
|
-38.51% (-121,376)
|
|||
|
2023 Q2
|
4.79%
|
$94.33
|
-4.51% (-14,897)
|
|||
|
2023 Q1
|
4.63%
|
$82.73
|
-1.11% (-3,690)
|
|||
|
2022 Q4
|
4.57%
|
$74.61
|
+0.64% (+2,133)
|
|||
|
2022 Q3
|
5.16%
|
$82.63
|
-2.66% (-9,062)
|
|||
|
2022 Q2
|
5.60%
|
$95.09
|
-4.89% (-17,531)
|
|||
|
2022 Q1
|
5.95%
|
$117.72
|
+1.44% (+5,071)
|
|||
|
2021 Q4
|
6.07%
|
$129.55
|
-25.28% (-119,478)
|
|||
|
2021 Q3
|
7.55%
|
$113.21
|
-2.26% (-10,909)
|
|||
|
2021 Q2
|
7.26%
|
$103.57
|
-5.91% (-30,352)
|
|||
|
2021 Q1
|
6.62%
|
$83.64
|
-13.63% (-81,068)
|
|||
|
2020 Q4
|
8.07%
|
$91.23
|
-5.82% (-36,762)
|
|||
|
2020 Q3
|
7.97%
|
$79.82
|
-5.51% (-36,824)
|
|||
|
2020 Q2
|
7.83%
|
$69.11
|
-6.05% (-43,058)
|
|||
|
2020 Q1
|
8.48%
|
$62.87
|
-36.59% (-410,586)
|
|||
|
2019 Q4
|
8.85%
|
$77.76
|
-21.87% (-314,181)
|
|||
|
2019 Q3
|
9.33%
|
$73.30
|
-7.98% (-124,512)
|
|||
|
2019 Q2
|
8.14%
|
$61.58
|
-21.27% (-421,578)
|
|||
|
2019 Q1
|
9.23%
|
$63.78
|
-19.52% (-480,939)
|
|||
|
2018 Q4
|
8.35%
|
$51.06
|
+0.27% (+6,516)
|
|||
|
2018 Q3
|
7.15%
|
$58.03
|
-8.13% (-217,350)
|
|||
|
2018 Q2
|
6.55%
|
$48.52
|
-21.28% (-722,793)
|
|||
|
2018 Q1
|
7.27%
|
$46.51
|
-15.48% (-622,263)
|
|||
|
2017 Q4
|
6.11%
|
$37.57
|
-0.24% (-9,855)
|
|||
|
2017 Q3
|
5.01%
|
$36.44
|
+55.92% (+1,445,097)
|
|||
|
2017 Q2
|
3.12%
|
$39.41
|
-24.25% (-827,172)
|
|||
|
2017 Q1
|
2.75%
|
$31.36
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.